Trends in the Early Diagnosis of Cardiovascular Disease: Worldwide Market Opportunities

   Single User - $3,250

Published Oct 1, 2001 | 211 Pages | Pub ID: KLI450532

Despite dramatic improvements in both diagnosis and therapy, cardiovascular disease remains the leading cause of mortality in the developed world. Worldwide more than $54 billion was spent on cardiac care therapeutics in 1999, with an expected 10% annual increase for the next 10 to 15 years. Furthermore, U.S. government statistics indicate that approximately $4 billion of unnecessary medical costs are spent each year on the assessment of non-cardiac cases in hospital emergency departments. As the population ages, this unnecessary expenditure is expected to double.

Because of these vast utilization costs, there is a move to use resources in the early diagnosis of disease risk that will allow for prevention, early intervention with therapeutics and lifestyle changes, and proactive disease management. The laboratory and imaging diagnostics industries will have substantial impact on the early selection of heart disease candidates.

On the in vitro diagnostics front, a menu of lipid tests, hypercoagulation factors, enzyme and protein markers, genetic markers, and even exposure to viral infections all contribute to the risk assessment initiative. The world cardiac rapid assay market is expected to achieve an average annual growth rate of 20% to 25% for the near future, driven by a host of new markers (ultra sensitive CRP, homocystein, plasminogen-activator inhibitors, s100 protein, p-selectin, soluble fibrin, glycogen phosphorylase-BB, thrombus precursor protein, and recently discovered genetic factors). In addition, the possible involvement of infectious agents in heart disease offers another opportunity for in vitro diagnostics.

Emerging in vivo testing, including imaging techniques such as ultrasound, MRI, PET, and CT, are now capable of uncovering plaque build up and heart function irregularities long before patients show clinical symptoms. The world market for functional cardiac imaging will see an annual average growth of 20% over the next 5 years.

Combining the information from biochemical markers, imaging, clinical parameters, ECG, and other parameters via information technology will enhance and help develop better intervention strategies. In the United States alone, cardiovascular telemedicine generated approximately $75 million in 2000.

Trends in the Early Diagnosis of Cardiovascular Disease examines these emerging markets and opportunities in-depth, including market size and potential. It contains a comprehensive listing of companies and organizations involved in the various market segments along with detailed company profiles of the largest and most important companies active in these market segments:

  • cardiac in vitro diagnostics (coagulation, proteins, genes, lipids)
  • proactive diagnostic imaging systems
  • cardiac risk assessment information technology
  • home cardiovascular monitoring systems

Chapter 1: Executive Summary

  • Scope and Methodology
  • In Vitro and In Vivo Tests for Early CVD
  • Size and Growth of the Market
  • Market Trends

Chapter 2: Introduction

  • 21st Century Disease Management Paradigm: Cardiovascular Tests, Genes, Imaging, and Bioinformatics
  • The Pros and Cons of Early Diagnosis
  • Point of View

Chapter 3: Trends and Issues

  • Background and Epidemiology
    • Market Population Trends in Major World Markets
    • World Cardiac Disease Demographics
    • North America
    • Africa and Asia
    • Latin America
    • Europe
  • Specific Disease Statistics
    • Deep Vein Thrombosis
    • Coronary Artery Disease
    • Hypertension
    • Congestive Heart Failure
    • Stroke
  • Human Genomics in Early CVD Assessment
  • Home Telemedicine Initiatives
  • Bioinformatics and Risk Assessment
  • Technology, Patient Outcomes, and Reimbursement Issues

Chapter 4: In Vitro Tests for Early CVD Diagnosis

  • Market Overview
    • Total Market
    • Geographic Analysis
    • Market Penetration
    • Cell Necrosis Enzymes
    • Coagulation Factors
    • Homocysteine
    • D-Dimer
    • High-Sensitivity C-Reactive Protein and Inflammation Markers
    • Lipids
    • Specific Enzymes and Proteins
    • Genes
    • Viral Infections
  • Commercial Outlook

Chapter 5: In Vitro Company Profiles

  • Agen Biomedical Ltd
  • American Biogenetic Sciences Inc
  • Axis-Shield Diagnostics Ltd
  • Biopool International Inc (see Xtrana Inc)
  • Biosite Diagnostics Inc
  • Cholestech Corp
  • Competitive Technologies Inc
  • CompuCyte Corp
  • Corgenix Medical Corp
  • CV Technologies Inc
  • Dade Behring Inc
  • diaDexus Inc
  • Ischemia Technologies Inc
  • LipoMed Inc
  • Myriad Genetics Inc
  • Sigma Diagnostics
  • Spectral Diagnostics
  • SYN X Pharma Inc
  • Third Wave Technologies Inc
  • Xtrana Inc

Chapter 6: In Vivo Diagnostics—Imaging and Assessment DEVICES

  • Background
    • Coronary Artery Disease
    • Peripheral Vascular Disease
  • Market Overview
  • Electrocardiography, Stress Tests, and Holter Monitors
  • Heart Rate, Blood Flow, Hemodynamics, and Electrophysiology
  • Nuclear Cardiology—X-ray Angiograph
  • Ultrasound
  • Magnetic Resonance Imaging
  • Computed Tomography
  • Positron Emission Tomography
  • Three-Dimensional Imaging
  • Contrast Agents
  • Commercial Outlook

Chapter 7: In Vivo Company Profiles

  • ATL Ultrasound—Advanced Technology Laboratories Inc
  • Boston Medical Technologies Inc
  • Boston Scientific (see Cardiac Pathways Corp)
  • Cambridge Heart Inc
  • Cardiac Mariners Inc (see NexRay Inc)
  • Cardiac Pathways Corp
  • CardioDynamics International Corp
  • Deltex Medical, Ltd
  • EP MedSystems Inc
  • FONAR Corp
  • Hypertension Diagnostics Inc
  • Imatron Inc
  • Itamar Medical Ltd
  • NexRay Inc
  • Royal Philips Electronics (see ATL Ultrasound—Advanced Technology
  • Laboratories Inc)
  • SonoSite Inc
  • Vital Images Inc
  • Volumetrics Medical Imaging

Chapter 8: Conclusions and Strategic Implications

  • Early Detection and Cost Savings
    • Conclusion
    • Implication
  • In Vitro Panels Remain Imperative
    • Conclusion
    • Implication
  • The Role of In Vivo Testing
    • Conclusion
    • Implication
  • Telehealth
    • Conclusion
    • Implication
  • Nature of Competitors
    • Conclusion
    • Implication
  • Cost-Benefit Analyses
    • Conclusion
    • Implication
  • Consumerism
    • Conclusion
    • Implication

Appendix A: Selected Cardiac In Vitro Diagnostic Products Available and in Development

Appendix B: Selected Cardiac In Vivo Diagnostic Products Available and in Development

Appendix C: Company Directory

List of Exhibits
Chapter One: Executive Summary
Table 1-1: Worldwide Market for Selected Cardiac In Vitro Diagnostics: 2000-2005
Table 1-2: Worldwide In Vivo Cardiac Diagnostic Procedures by Type: 2000-2005
Chapter Three: Trends and Issues
Table 3-1: Selected Genetic Tests and Therapeutic Targets
Table 3-2: Selected Companies Developing Cardiovascualar Genomic
Chapter Four: In Vitro Tests for Early CVD Diagnosis
Table 4-1: Selected In Vitro Diagnostic Markers for CVD
Table 4-2: Selected CVD Drug Targets
Table 4-3: Worldwide Market for Selected Cardic In Vitro Diagnostics: 2000-2005
Figure 4-1: Worldwide Market for Cardiac In Vitro Diagnostics, Market Share by Test Type: 2000
Figure 4-2: Worldwide Market for Cardiac In Vitro Diagonistics, Market Share by Test Type: 2005
Figure 4-3: Worldwide Market for Cardiac In Vitro Diagnostics, Revenue Distribution by Region: 2005
Figure 4-4: Technology Penetration Forecast for Cardiac In Vitro Diagnostics: 2000-2010
Table 4-4: Reported Serum Marker Cut-Off Values
Table 4-5: Cut-off, Percentile, and Coefficient of Variation for Leading Troponin Assays
Chapter Six: In Vivo Diagnostics—Imaging and Assessment Devices
Table 6-1: In Vivo CVD Test Techniques
Table 6-2: Worldwide In Vivo Cardiac Diagnostic Procedures by Type: 2000-2005
Figure 6-1: Worldwide Market for Cardiac In Vivo Diagnostics, Market Share by Test Type: 2000
Figure 6-2: Worldwide Market for Cardiac In Vivo Diagnostics, Market Share by Test Type: 2005
Figure 6-3: Technology Penetration Forecast for Cardiac In Vivo Diagnostics 2000-2010

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.